Behbahani Ali’s SEC Form 4 activity across 51 filings paints a picture of a heavily acquisition-oriented investor with a strong bullish bias. The most striking signal is a single open-market purchase of $15 million in SGP on February 9, 2026, which dwarfs all other transactions and accounts for nearly the entirety of his disclosed buying. That purchase, paired with a series of derivative conversions (code C) on the same date, suggests a deliberate deployment of capital into that name. In contrast, his total open-market sales amount to just $253,708, a fraction of his buying, indicating no meaningful distribution phase. The bulk of his other activity consists of grants and awards (code A) — compensation events with no cash outlay — across a portfolio of biotech and genomics names including BDTX, KRRO, NKTX, CRSP, and GLUE.
The recent filings show a flurry of zero-value awards and conversions rather than fresh cash commitments. In late June and early July 2026, Ali received awards in GLUE, BDTX, KRRO, NKTX, and CRSP, with the only notable dollar figure being $14,875 in BDTX on June 19. Earlier, on March 10, 2026, he received two large awards in KRRO valued at roughly $2.7 million and $2.3 million, suggesting a significant equity stake in that company. His only sales in the trailing period were code D transactions — dispositions back to the issuer — in ACLX on April 28, 2026, and NEUE on October 2, 2025, all valued at zero, which are typically administrative rather than market-driven. The pattern is consistent: Ali is accumulating through purchases and compensation, not selling into strength, with the SGP purchase standing as the clearest expression of conviction.
AI-assisted summary